Dark

NTRA
Natera, Inc. Common Stock
stock NASDAQ

At Close

Jun 6, 2025 3:59:51 PM EDT

163.85USD-1.000%(-1.66)1,016,925

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 6, 2025 8:33:30 AM EDT

167.20USD+1.021%(+1.69)754

After-hours

Jun 6, 2025 4:00:30 PM EDT

163.76USD+0.006%(+0.01)18,866

OverviewOptionsHistoricalExchangesShortsNews

Jan 22, 2022

10:19PM EST The Landmark CIRCULATE-Japan Study Showed Natera Inc.'s (NTRA) Signatera MRD Test is predictive of chemotherapy benefit in Colorectal Cancer. RTTNews

02:22PM EST Landmark CIRCULATE-Japan Study Shows Natera's Signatera(tm) MRD Test is PR Newswire

Jan 20, 2022

08:38AM EST Natera's Highlights SMART Study; Says Study Demonstrates High Accuracy Of Co's Panorama NIPT For 22q11.2 Deletion Screening Benzinga

Jan 19, 2022

08:34AM EST Natera to Present Latest Signatera(tm) MRD Data in Colorectal and Pancreatic PR Newswire

Jan 6, 2022

08:46AM EST Natera Reports Expansion Into Early Cancer Detection Market Benzinga

08:33AM EST Natera Announces Expansion Into Early Cancer Detection and Screening Business Wire

Jan 4, 2022

08:34AM EST Natera to Webcast Live Presentation at the 40th Annual J.P. Morgan Healthcare PR Newswire

Jan 3, 2022

08:34AM EST Signatera(tm) Wins Fierce Life Sciences Innovation Award PR Newswire

Dec 9, 2021

09:48PM EST Natera Presents Latest Signatera MRD Data In Breast Cancer At SABCS 2021 Dec. 7-10 Benzinga

09:04AM EST Natera Presents Latest Signatera(tm) MRD Data in Breast Cancer at SABCS 2021 PR Newswire

Nov 19, 2021

09:01AM EST Natera Reports Its Panorama SMART Study Results Accepted For Publication By American Journal Of Obstetrics, Gynecology Benzinga

09:01AM EST Natera's Panorama SMART Study Results Accepted for Publication by the American PR Newswire

Nov 11, 2021

11:52AM EST Medicare Publishes Final Local Coverage Determination for Pan-Cancer PR Newswire

Nov 5, 2021

09:26AM EDT Natera Sees FY21 Sales $615M-$625M vs $614.7M Estimate Benzinga

09:26AM EDT Natera Q3 EPS $(1.63) Misses $(1.27) Estimate, Sales $158.10M Beat $151.36M Estimate Benzinga

Nov 4, 2021

04:07PM EDT Natera Reports Third Quarter 2021 Financial Results PR Newswire

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 3, 2021

09:20AM EDT Natera Highlights Publication Of Initial Results Of Trifecta Study Benzinga

08:33AM EDT Natera Validates Prospera(tm) With Quantification in Multi-Site, Prospective PR Newswire

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

08:33AM EDT Natera Announces Third Quarter 2021 Earnings Conference Call PR Newswire

Oct 18, 2021

08:35AM EDT Natera Reports Commercial Launch Of Prospera Lung Transplant Assessment Test Benzinga

08:33AM EDT Natera Expands Organ Health Business With Commercial Launch of the Prospera(tm) PR Newswire

Oct 11, 2021

08:42AM EDT Natera Announces New Publication It Says Validates Signatera Velocity Metric To Improve Cancer Management Benzinga

08:36AM EDT Natera : Study In Stage III Colorectal Cancer Demonstrates Prognostic Value Of CtDNA Growth Rate RTTNews

08:33AM EDT Natera Announces New Publication Validating Signatera(r) Velocity Metric to PR Newswire

Oct 6, 2021

08:38AM EDT Natera Completes Largest Prospective Validation Study Of Commercial Cell-Free DNA Test In Lung Transplantation RTTNews

08:36AM EDT Natera Reports Completion Of Its Validation Study Of A Commercial Cell-Free DNA Test In Lung Transplants Benzinga

08:33AM EDT Natera Announces Completion of the Largest Prospective Validation Study of a PR Newswire

Sep 29, 2021

12:31AM EDT Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents PR Newswire

Sep 17, 2021

08:40AM EDT Natera : Data Suggests CtDNA Dynamics May Be Better Surrogate Of Overall Survival Than Radiographic Imaging RTTNews

08:38AM EDT Natera Releases New Clinical Data At ESMO 2021 In Gastroesophageal Cancer And Uveal Melanoma Benzinga

08:33AM EDT Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and PR Newswire

Sep 9, 2021

08:33AM EDT Natera Launches Prospera(tm) Kidney with Quantification to Further Improve Test PR Newswire

Sep 7, 2021

06:12AM EDT Natera Agrees With NRG Oncology To Use Signatera Personalized Molecular Residual Disease Test In NRG-GI008 RTTNews

06:03AM EDT Natera's Signatera(r) Test Selected for NRG Oncology's Landmark CIRCULATE-US PR Newswire

Aug 31, 2021

08:34AM EDT Natera Announces Validation And Launch Of Prospera Heart Transplant Assessment Test RTTNews

08:31AM EDT Natera Announces the Validation and Launch of the Prospera(tm) Heart Transplant PR Newswire

08:31AM EDT Natera Announces Validation And Launch Of The Prospera Heart Transplant Assessment Test Benzinga

Aug 30, 2021

11:11AM EDT Return on Capital Employed Overview: Natera Benzinga

Aug 10, 2021

09:05AM EDT Natera to Participate in Upcoming Investor Conferences PR Newswire

Aug 6, 2021

10:40AM EDT Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook Benzinga

Aug 5, 2021

04:33PM EDT Natera Sees FY21 Sales $600M-$620M vs $567.6M Estimate Benzinga

04:32PM EDT Natera Q2 EPS $(1.32) Misses $(1.08) Estimate, Sales $142.00M Beat $127.49M Estimate Benzinga

04:07PM EDT Natera Reports Second Quarter 2021 Financial Results PR Newswire

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 4, 2021

09:06AM EDT Natera Reports Use Of Signatera As Companion Diagnostic In GlaxoSmithKline's Phase 3 ZEST Trial For Niraparib In Early-Stage Breast Cancer Benzinga

09:05AM EDT Natera Announces Use Of Signatera As Companion Diagnostic In GSK's Phase III ZEST Trial For Niraparib In Breast Cancer RTTNews

09:04AM EDT Natera Announces Use of Signatera(r) as a Companion Diagnostic in GSK's Phase PR Newswire

Aug 3, 2021

08:20AM EDT What Does Natera's Debt Look Like? Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

09:04AM EDT Natera Announces Second Quarter 2021 Earnings Conference Call PR Newswire

Jul 28, 2021

09:04AM EDT New Study Validates the Signatera(r) MRD Test and Demonstrates its Clinical PR Newswire

09:04AM EDT Natera Reports New Study Validates Signatera Molecular Residual Disease Test Benzinga

Jul 27, 2021

12:50PM EDT 3 Stocks Insiders Are Buying Benzinga

Jul 22, 2021

09:21AM EDT Natera Says Encouraged By Performance Of Signatera In Setting Of Oligometastatic Colorectal Cancer RTTNews

09:03AM EDT New Publication Shows 96% Overall Survival Among Metastatic Colorectal Cancer PR Newswire

09:01AM EDT Natera Highlights Publication Of New Peer-Reviewed Study Validating Molecular Residual Disease Assay, Signatera, Showed 96% Overall Survival In Metastatic Colorectal Cancer Patients Benzinga

05:23AM EDT Natera Priced 4.5M Share Secondary Offering @$113/Share Benzinga

12:33AM EDT Natera Prices Public Offering Of 4.5 Mln Shares Of Common Stock At $113/Shr RTTNews

12:29AM EDT Natera Announces Pricing of Follow-On Offering PR Newswire

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

05:07PM EDT Natera Launches Proposed Follow-On Offering Of $350M Shares Of Common Stock Benzinga

05:07PM EDT Natera Launches Proposed Follow-On Offering PR Newswire

05:00PM EDT Natera Files For Stock Shelf Of Up To $350M Benzinga

11:41AM EDT Expert Ratings For Natera Benzinga

08:41AM EDT Craig-Hallum Maintains Buy on Natera, Raises Price Target to $139 Benzinga

Jul 19, 2021

10:25AM EDT Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings Benzinga

08:50AM EDT Natera Sees Prelim Q2 Total Revenues $138M-$141M, Product Revenues $135M-$137M Benzinga

08:49AM EDT Natera Expects Q2 Loss From Operations Of $113 Mln To $117 Mln Vs. Loss $51.7 Mln Prior Year RTTNews

08:47AM EDT Natera Reports Preliminary Second Quarter 2021 Results PR Newswire

Jul 6, 2021

08:29AM EDT Piper Sandler Maintains Overweight on Natera, Raises Price Target to $155 Benzinga

Jul 2, 2021

11:03AM EDT Natera : Data Shows More Than 99% Of MRD-negative Patients Recurrence-free At 6 Months Of Follow-up RTTNews

11:01AM EDT Natera Says New Results From Prospective CIRCULATE Trial 'Expand Clinical Utility Of The Signatera MRD Test In Colorectal Cancer' Benzinga

11:01AM EDT New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical PR Newswire

Jun 24, 2021

09:10AM EDT Natera And BGI Genomics Announce Commercial Launch Of BGI/Natera Signatera Assay In China RTTNews

09:06AM EDT Natera And BGI Genomics Highlights Commercial Launch Of The BGI/Natera Signatera Assay In China Benzinga

09:04AM EDT Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera PR Newswire

Jun 23, 2021

09:34AM EDT BTIG Maintains Buy on Natera, Raises Price Target to $155 Benzinga

Jun 22, 2021

11:50AM EDT Analyst Ratings For Natera Benzinga

10:05AM EDT SVB Leerink Maintains Outperform on Natera, Raises Price Target to $160 Benzinga

Jun 21, 2021

07:53AM EDT 10 Biggest Price Target Changes For Monday Benzinga

07:16AM EDT Wells Fargo Maintains Overweight on Natera, Raises Price Target to $125 Benzinga

06:27AM EDT SVB Leerink Maintains Outperform on Natera, Raises Price Target to $160 Benzinga

Jun 18, 2021

09:08AM EDT Natera Granted Advanced Diagnostic Laboratory Test Status For Signatera MRD Test From CMS RTTNews

09:04AM EDT Natera Reports Centers For Medicare & Medicaid Services Granted Advanced Diagnostic Lab Test Status For Its Signatera Molecular Residual Disease Test Benzinga

09:03AM EDT Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its PR Newswire

Jun 16, 2021

11:22AM EDT Natera Highlights Publication Of Prospective, Randomized Study Validating Signatera For Prediction Of Immunotherapy Benefit In Nature Journal Benzinga

11:21AM EDT Nature Journal Publishes Prospective, Randomized Study Validating Signatera(r) PR Newswire

Jun 15, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 Benzinga

08:16AM EDT Raymond James Initiates Coverage On Natera with Market Perform Rating Benzinga

Jun 8, 2021

07:10AM EDT Foundation Medicine Launches FoundationOneTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera Benzinga

07:03AM EDT Foundation Medicine Launches FoundationOne(r)Tracker ctDNA Monitoring Assay for PR Newswire

Jun 4, 2021

09:04AM EDT Natera Announces New Prospera Data At ATC 2021 Virtual Connect Conference Benzinga

09:03AM EDT Natera Announces New Prospera(tm) Data at the ATC 2021 Virtual Connect PR Newswire

May 28, 2021

04:59PM EDT Natera Calls Advertising Claim Against Guardant 'Meritless Suit,' 'Misleading' Benzinga

04:53PM EDT Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against PR Newswire

May 26, 2021

09:46AM EDT Natera To Present New Clinical Data On Personalized And Tumor-informed Molecular Residual Disease Assay, Signatera RTTNews

09:10AM EDT Natera To Present At American Society Of Clinical Oncology Meeting Jun. 4-8 Benzinga

09:04AM EDT New Signatera(tm) Data in Multiple Myeloma, Colorectal Cancer and Ovarian PR Newswire

May 25, 2021

10:51AM EDT Expert Ratings for Natera Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 Benzinga

09:44AM EDT Truist Securities Maintains Buy on Natera, Lowers Price Target to $129 Benzinga

07:17AM EDT Wells Fargo Initiates Coverage On Natera with Overweight Rating, Announces Price Target of $110 Benzinga

May 20, 2021

09:37AM EDT Natera To Present Clinical Data From Largest Prospective MRD-Guided Trial In Colorectal Cancer RTTNews

09:07AM EDT Natera To Present Clinical Data From Trial In Colorectal Cancer At The 2021 ASCO Annual Meeting Benzinga

09:04AM EDT Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in PR Newswire

May 10, 2021

10:15AM EDT Morgan Stanley Maintains Overweight on Natera, Lowers Price Target to $135 Benzinga

May 7, 2021

10:02AM EDT BTIG Maintains Buy on Natera, Raises Price Target to $150 Benzinga

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

04:47PM EDT Natera: Q1 Earnings Insights Benzinga

04:47PM EDT Natera Sees FY21 Revs $550M-$575M Vs $514.68M Est; Sees 2021 Gross Margin ~52%-55% Of Revenues Benzinga

04:12PM EDT Natera Q1 EPS $(0.74) Beats $(1.02) Estimate, Sales $152.30M Beat $114.37M Estimate Benzinga

04:06PM EDT Natera Reports First Quarter 2021 Financial Results PR Newswire

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 3, 2021

09:07AM EDT Natera To Present New Colorectal Cancer And Multiple Myeloma Data At The 2021 Annual ASCO Meeting Jun. 4-8 Benzinga

09:03AM EDT Natera to Present New Colorectal Cancer and Multiple Myeloma Data at the 2021 PR Newswire

Apr 29, 2021

09:03AM EDT Natera Announces First Quarter 2021 Earnings Conference Call PR Newswire

Apr 22, 2021

11:22AM EDT Natera Shares Quiet Following Co. Press Release Highlighting Co. Received 'pathway to future coverage for the Prospera donor-derived, cell-free DNA test to determine transplant rejection status in multiple organs' Benzinga

11:21AM EDT Prospera(tm) Transplant Assessment Test: Path Established to Expand Future PR Newswire

Apr 7, 2021

09:57AM EDT Natera Implements First Wave of Panorama(r) AI Improvements With Immediate PR Newswire

09:57AM EDT Natera Reports Implementation Of First Wave Of Panorama AI Innovations Benzinga

Mar 31, 2021

09:12AM EDT Natera and Tesis Labs Announce Prenatal Genetic Testing Collaboration; Financial Details Not Disclosed Benzinga

09:09AM EDT Natera And Tesis Labs Enter Strategic Collaboration On Prenatal Genetic Testing RTTNews

09:08AM EDT Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic PR Newswire

Mar 24, 2021

10:09AM EDT Natera shares were trading higher after the company announced the FDA granted two Breakthrough Device Designations covering new intended uses of the Signatera molecular residual disease test. Benzinga

09:06AM EDT FDA Grants Two Breakthrough Device Designations For Natera's Signatera MRD Test RTTNews

09:04AM EDT FDA Grants Two New Breakthrough Device Designations For Natera's Signatera MRD Test Benzinga

09:04AM EDT FDA Grants Two New Breakthrough Device Designations for Natera's Signatera(tm) PR Newswire

Mar 10, 2021

09:11AM EST Natera, Genentech Initiate Phase III Trial Using Signatera As Companion Diagnostic For Atezolizumab RTTNews

09:08AM EST Natera And Genentech Initiate Phase III Trial Using Signatera As A Companion Diagnostic For Atezolizumab In Early-Stage Muscle-Invasive Bladder Cancer Benzinga

09:03AM EST Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder Cancer PR Newswire

Mar 1, 2021

09:17AM EST Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $140 Benzinga

Feb 26, 2021

11:19AM EST Piper Sandler Maintains Overweight on Natera, Raises Price Target to $150 Benzinga

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Feb 25, 2021

04:35PM EST Natera: Q4 Earnings Insights Benzinga

04:34PM EST Natera Sees FY21 Sales $500M-$525M Vs $469.31M Estimates Benzinga

04:32PM EST Natera Q4 EPS $(0.89) Misses $(0.62) Estimate, Sales $112.40M Beat $106.62M Estimate Benzinga

04:25PM EST Natera Reports Fourth Quarter and Year 2020 Financial Results PR Newswire

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 23, 2021

09:05AM EST Natera to Participate in the Cowen 41st Annual Health Care Conference PR Newswire

Feb 18, 2021

09:04AM EST Natera Announces Fourth Quarter and Fiscal 2020 Earnings Conference Call PR Newswire

Feb 17, 2021

09:04AM EST Natera And Personalis Announce Personalized Oncology Partnership Benzinga

09:03AM EST Natera and Personalis Partner for Personalized Monitoring in Oncology PR Newswire

Feb 11, 2021

09:04AM EST Natera to Participate in Upcoming Investor Conferences PR Newswire

Feb 3, 2021

09:10AM EST Natera Highlights Presentation Of Results From SMART Study At MFM 41st Annual Pregnancy Meeting Benzinga

09:08AM EST Panorama SMART Study Confirms Performance In Largest Prospective NIPT Trial To Date RTTNews

09:04AM EST Panorama(r) SMART Study Confirms Market-Leading Performance in Largest PR Newswire

Feb 1, 2021

09:05AM EST Natera Highlights Presentation Of Results From SMART Study At SMFM 41st Annual Pregnancy Meeting Benzinga

09:03AM EST SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected PR Newswire

Jan 28, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2021 Benzinga

07:12AM EST Truist Securities Initiates Coverage On Natera with Buy Rating, Announces Price Target of $143 Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

03:06PM EST Natera Reports Filed Patent Infringement Suit Against Inivata Benzinga

03:05PM EST Natera Files Patent Infringement Suit Against Inivata PR Newswire

09:56AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

06:52AM EST SVB Leerink Maintains Outperform on Natera, Raises Price Target to $140 Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

10:36AM EST New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial PR Newswire

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 12, 2021

09:05AM EST Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium PR Newswire

Jan 5, 2021

09:03AM EST Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare PR Newswire

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 18, 2020

09:09AM EST US Patent Office Upholds Validity Of Natera's Early Priority Date '592 cfDNA Patent Benzinga

09:03AM EST U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA PR Newswire

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 9, 2020

09:15AM EST Natera : Signatera Can Identify MIUC Patients Likely To Benefit From Adjuvant Treatment With Atezolizumab RTTNews

09:05AM EST New Signatera Data To Be Presented At 2020 ESMO IO Congress From Phase III IMvigor010 Trial Benzinga

09:03AM EST New Signatera(tm) Data to be Presented at the 2020 ESMO IO Congress from the PR Newswire

Dec 8, 2020

09:04AM EST Natera to Present New Immunotherapy Monitoring Data at SABCS 2020 PR Newswire

Dec 3, 2020

09:04AM EST Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All PR Newswire

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Dec 1, 2020

10:35AM EST Natera Reports The Largest Health Plan In US Has Extended Coverage Of Noninvasive Prenatal Testing To All Pregnancies Benzinga

10:32AM EST Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for PR Newswire

Nov 30, 2020

09:06AM EST Natera:I-SPY 2 Trial Highlights Signatera's Ability To Predict Treatment Outcomes In Neoadjuvant Breast Cancer Patients RTTNews

09:04AM EST Natera Highlights New Publication From I-SPY 2 Trial On Co's Signatera's Ability To Predict Treatment Outcomes In Neoadjuvant Breast Cancer Patients Benzinga

09:03AM EST New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict PR Newswire

Nov 19, 2020

09:06AM EST Natera Appoints Monica Bertagnolli To Its Board Of Directors RTTNews

09:05AM EST Natera Appoints Dr. Monica Bertagnolli to its Board of Directors PR Newswire

Nov 13, 2020

10:34AM EST SVB Leerink Maintains Outperform on Natera, Raises Price Target to $95 Benzinga

Nov 12, 2020

09:04AM EST Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum PR Newswire

Nov 10, 2020

09:06AM EST Natera Highlights Presentation Of New Data At 2020 SITC Annual Meeting Highlighting Applications Of Personalized ctDNA Testing In Immunotherapy Treatment Monitoring Benzinga

09:05AM EST Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring PR Newswire

Nov 6, 2020

11:48AM EST Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $87 Benzinga

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

04:48AM EST SVB Leerink Maintains Outperform on Natera, Raises Price Target to $84 Benzinga

Nov 5, 2020

04:49PM EST Natera Sees FY20 Sales $380M-$390M vs $359.49M Est. Benzinga

04:48PM EST Natera Q3 EPS $(0.72) Misses $(0.68) Estimate, Sales $98.10M Beat $87.24M Estimate Benzinga

04:06PM EST Natera Reports Third Quarter 2020 Financial Results PR Newswire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

09:07AM EDT Natera Highlights Recent Int'l. Society For Prenatal Diagnosis Position Statement Recommending Use Of cfDNA Screening IN Twin Pregnancies Benzinga

09:03AM EDT International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin PR Newswire

Oct 29, 2020

01:05PM EDT Natera Announces Third Quarter 2020 Earnings Conference Call PR Newswire

09:04AM EDT NIPT for Average Risk Now Covered for 139 Million Commercial Lives PR Newswire

Oct 21, 2020

09:05AM EDT Natera to Present New Data At ASN Kidney Week 2020 Oct. 22-25 Showing Clinical Differentiation Of the Prospera Test Benzinga

09:04AM EDT Natera to Present New Data at ASN Kidney Week 2020 Showing Clinical PR Newswire

Oct 8, 2020

10:00AM EDT Benzinga's Top Upgrades, Downgrades For October 8, 2020 Benzinga

09:03AM EDT Natera's Panorama(r) NIPT Receives Average Risk Coverage for an Additional 24 PR Newswire

05:48AM EDT BTIG Initiates Coverage On Natera with Buy Rating, Announces Price Target of $90 Benzinga

Oct 5, 2020

09:13AM EDT Disease Awareness Challenge PR Newswire

09:03AM EDT Natera Says Court Rejects ArcherDX's Motion To Dismiss Co's Patent Infringement Case Benzinga

09:03AM EDT Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case PR Newswire

Oct 2, 2020

09:17AM EDT Natera: Signatera Molecular Residual Disease Test To Be Used In The DARE Study RTTNews

09:04AM EDT Natera Announces Prospective Randomized Clinical Trial To Evaluate Palbociclib In Early Stage Breast Cancer Patients Who Test Positive With Signatera Benzinga

09:03AM EDT Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib PR Newswire

Sep 28, 2020

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 28, 2020 Benzinga

06:36AM EDT Morgan Stanley Initiates Coverage On Natera with Overweight Rating, Announces Price Target of $80 Benzinga

Sep 24, 2020

03:50PM EDT Natera Announces Medicare Issues Draft Local Coverage Determination For Signatura In Immunotherapy Response Monitoring Benzinga

03:50PM EDT Medicare Issues Draft Local Coverage Determination for Signatera(tm) in PR Newswire

02:56PM EDT Natera Shares Up 5.8% For Session; Hearing Craig Hallum Raises Price Target From $66 To $82; Reiterates Buy Benzinga

Sep 18, 2020

09:05AM EDT Natera Reports Will Present New Data On Personalized Molecular Residual Disease Test, Signatera, At European Society For Medical Oncology Sept. 19-21 Benzinga

09:03AM EDT Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting PR Newswire

Sep 17, 2020

09:41AM EDT Benzinga's Top Upgrades, Downgrades For September 17, 2020 Benzinga

06:21AM EDT SVB Leerink Initiates Coverage On Natera with Outperform Rating, Announces Price Target of $75 Benzinga

Sep 14, 2020

09:10AM EDT Natera Highlights Launch Of Initiative To Transform Mgmt. Of Cancer Patients In Organ Transplants Benzinga

09:03AM EDT Natera Launches Initiative to Transform the Management of Cancer Patients in PR Newswire

Sep 11, 2020

09:08AM EDT Natera Reports Medicare Admin. Contractor For Northern California, Noridian, Finalized Final Local Coverage ARticle To Provide Medicare Benefits For Serial Use Of Signatera Molecular Residual Disease Test In Patients With History Of Colorectal Cancer Benzinga

09:03AM EDT Natera's Signatera(tm) MRD Test Receives a Final Coverage Decision from PR Newswire

12:56AM EDT Natera Prices Public Offering Of 4.17 Mln Shares At $60/Shr RTTNews

12:54AM EDT Natera Announces Pricing of Follow-On Offering PR Newswire

Sep 10, 2020

02:42PM EDT Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference PR Newswire

Sep 9, 2020

05:11PM EDT Natera Launches Proposed Follow-On Offering Of $250M Of Shares Of Common Stock Benzinga

05:08PM EDT Natera Launches Proposed Follow-On Offering PR Newswire

04:50PM EDT Natera Files For Stock Shelf Of Up To $250M Benzinga

Sep 3, 2020

10:38AM EDT Natera Reports Co Receives Final Medicare Coverage For Its Signatera MRD Test In Stage 2-3 Colorectal Cancer Benzinga

10:38AM EDT Natera Receives Final Medicare Coverage for its Signatera(tm) MRD Test in Stage PR Newswire

Sep 2, 2020

06:44PM EDT SMART Study Data for Aneuploidy and 22q Unblinded PR Newswire

Sep 1, 2020

09:05AM EDT Natera Highlights Study Showing 'Clinical Utility of the Prospera Test in Nephrology Practice Benzinga

09:04AM EDT Study Shows Clinical Utility of the Prospera(tm) Test in Nephrology Practice PR Newswire

Aug 27, 2020

09:13AM EDT Natera Announces Collaborative Agreement With MGCC Of Massachusetts General Hospital RTTNews

09:05AM EDT Natera Announces Collaboration With Massachusetts General Hospital For A Prospective Randomized Clinical Trial In Early Stage Breast Cancer Benzinga

09:03AM EDT Natera Announces Collaboration with Massachusetts General Hospital for a PR Newswire

Aug 26, 2020

09:07AM EDT Natera's Signatera Test Receives CE Mark Benzinga

Aug 18, 2020

09:11AM EDT Natera PR Confirms American College of Obstetrics and Gynecology And Society of Maternal Fetal Medicine Joint Guideline For Use Of Non-Invasive Prenatal Testing For Pregnant Women Benzinga

09:04AM EDT Joint Guideline from ACOG and SMFM Supports use of Non-Invasive Prenatal PR Newswire

Aug 17, 2020

02:17PM EDT Shares Of Natera Quiet; Hearing American Society Of Obstetricians & Gynecologists Issues New Guidelines On NIPT. BZ NOTE: Natera Makes NIPT Benzinga

Aug 14, 2020

08:26AM EDT The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga

Aug 13, 2020

12:10PM EDT Return On Capital Employed Overview: Natera Benzinga

Aug 7, 2020

09:06AM EDT Natera Files Patent Infringement Suit Against ArcherDX RTTNews